• Profile
Close

Association of serum ustekinumab levels with clinical response in psoriasis

JAMA Dermatology Nov 24, 2019

Tsakok T, Wilson N, Dand N, et al. - Among 491 individuals with psoriasis, researchers assessed the clinical utility of therapeutic drug monitoring for ustekinumab. From June 2009 to December 2017, patients with psoriasis were recruited to the multicenter Biomarkers of Systemic Treatment Outcomes in Psoriasis study within the British Association of Dermatologists Biologic and Immunomodulators Register. Findings suggested an association of early serum ustekinumab levels with a subsequent 75% decline from baseline in Psoriasis Area and Severity Index score, although this connection did not hold across other Psoriasis Area and Severity Index outcomes. Drug immunogenicity seemed to be low, with antidrug antibodies identified in only 17 of 490 patients. The results obtained from this prospective observational cohort indicate that early serum ustekinumab levels measurement may be helpful in guiding the psoriasis treatment approach. In determining the clinical outcome, adequate drug exposure early in the treatment cycle can be particularly significant.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay